Only in Titles

Search results for: AntiHuman

paperclip

#35014837   2022/01/03 To Up

Antibody-Functionalized Carnauba Wax Nanoparticles to Target Breast Cancer Cells.

Development of safer nanomedicines for drug delivery applications requires immense efforts to improve clinical outcomes. Targeting a specific cell, biocompatibility and biodegradability are vital properties of a nanoparticle to fulfill the safety criteria in medical applications. Herein, we fabricate antibody-functionalized carnauba wax nanoparticles encapsulated a hydrophobic drug mimetic, which is potentially interesting for clinical use due to the inert and nontoxic properties of natural waxes. The nanoparticles are synthesized applying miniemulsion methods by solidifying molten wax droplets and further evaporating the solvent from the dispersion. The pH-selective adsorption of antibodies (IgG1, immunoglobulin G1, and CD340, an antihuman HER2 antibody) onto the nanoparticle surface is performed for practical and effective functionalization, which assists to overcome the complexity in chemical modification of carnauba wax. The adsorption behavior of the antibodies is studied using isothermal titration calorimetry (ITC), which gives thermodynamic parameters including the enthalpy, association constant, and stoichiometry of the functionalization process. Both antibodies exhibit strong binding at pH 2.7. The CD340-decorated wax nanoparticles show specific cell interaction toward BT474 breast cancer cells and retain the targeting function even after 6 months of storage period.
Banu Iyisan, Johanna Simon, Yuri Avlasevich, Stanislav Baluschev, Volker Mailaender, Katharina Landfester

2049 related Products with: Antibody-Functionalized Carnauba Wax Nanoparticles to Target Breast Cancer Cells.

100ul 100ul100ul100ul1 module1 module1mg 100ul

Related Pathways

paperclip

#34882942   2021/12/09 To Up

Alloantibodies after simultaneous liver-kidney transplant: A story of primary nonfunction, retransplantation, and antibody-mediated rejection.

Simultaneous liver-kidney transplant (SLKT) in the presence of antihuman leukocyte antigen (HLA) donor-specific antibodies (DSA) is a well-accepted practice. Herein, we describe the evolution of alloantibodies in a patient who received an SLKT. The pre-SLKT serum sample showed multiple strong DSA. As expected, all DSA cleared in a sample collected 4 days after the SLKT. Because of the primary nonfunction of the liver in the SLKT, the patient had a second liver transplant 4 days later. An abrupt increase in DSA levels against the kidney was detected 10 days after the second liver transplant. These DSA were refractory to treatment, and the transplanted kidney was lost due to antibody-mediated rejection (AMR). A detailed study of the HLA epitopes recognized by DSA and, after normalization with third-party alloantibodies to address the effect of multiple transfusions and liver allograft neutralization, showed that the elimination of these antibodies depended on the HLA antigens expressed by the transplanted liver cells. The return of DSA after removal of the first transplanted liver was associated with AMR in the transplanted kidney.
Daniel S Ramon, Danielle M Troop, Theresa N Kinard, Caroline C Jadlowiec, Margaret S Ryan, Winston R Hewitt, Linda G Olsen, Andrés Jaramillo, Timucin Taner, Raymond L Heilman

1579 related Products with: Alloantibodies after simultaneous liver-kidney transplant: A story of primary nonfunction, retransplantation, and antibody-mediated rejection.

100ul100ug 125 ml 100ug100ul100 100ug100ug100ug100ug 500 ml

Related Pathways

paperclip

#34772490   2021/11/10 To Up

Impact of Anti-HLA De Novo Donor Specific Antibody on Graft Outcomes in Pancreas Transplantation: A Meta-Analysis.

The aim of this review is to provide consensus on the impact of antihuman leukocyte antigen (anti-HLA) de novo donor-specific antibodies (dnDSA) on pancreatic allograft loss.
Sualeh Muslim Khan, Ramish Sumbal, Austin D Schenk

2303 related Products with: Impact of Anti-HLA De Novo Donor Specific Antibody on Graft Outcomes in Pancreas Transplantation: A Meta-Analysis.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#34689117   2021/10/09 To Up

Bavachin produces immunoadjuvant activity by targeting the NFAT signaling pathway.

Bavachin, a flavonoid compound isolated from the seeds and fruits of Psoralea corylifolia l. (family Fabaceae), is used as a traditional medicine in Asia. Indeed, it is reported to have various medicinal functions such as estrogenic and antiinflammatory activities among others. However, to date, the effects of bavachin on T cell activation have yet to be reported.
Young-Hee Jin, Dong Eon Kim, Min Seong Jang, Jung Sun Min, Sunoh Kwon

1704 related Products with: Bavachin produces immunoadjuvant activity by targeting the NFAT signaling pathway.

2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box1.5 x 10^6 cells2 Pieces/Box2 Pieces/BoxInhibitors2 Pieces/Box2 Pieces/Box1.5x10(6) cells2 Pieces/Box

Related Pathways

paperclip

#34654786   // To Up

Trastuzumab-Induced Negative Chronotropic and Lusitropic Effects in Cynomolgus Monkeys.

Treatment with trastuzumab, an antihuman epidermal growth factor receptor type 2 humanized monoclonal antibody, has been associated with heart failure in certain patients with cancer; however, the mechanism underlying trastuzumab-induced cardiac dysfunction remains unclear. This study was conducted to clarify the cardiac effects of trastuzumab in cynomolgus monkeys, which are commonly used as cross-reactive species in preclinical safety evaluation. Monkeys were treated with trastuzumab weekly for 1 month (5 doses in total). At first and fifth doses for pressure-volume loop analysis, trastuzumab at 20 mg·kg-1·10 min-1, equivalent to the human therapeutic dose, was administered intravenously to isoflurane-anesthetized animals, followed by 60 mg·kg-1·10 min-1 at a 30-minute interval. The other doses were fixed at 80 mg·kg-1·10 min-1 under unanesthetized conditions. After the first dose, reduced heart rate, decreases in maximal rate of fall of left ventricular pressure, and prolonged time constant for isovolumic relaxation, which are predictors of drug-induced changes in lusitropy, were observed at 20 and 60 mg·kg-1. The changes after the fifth dose were comparable with those after the first dose, indicating trastuzumab did not show exacerbation of cardiac function during the 1-month trial. No significant changes in slope of preload recruitable stroke work, which is a load-independent inotropic parameter, were observed at either dose. In conclusion, trastuzumab-induced little inotropic effect but induced negative chronotropic or lusitropic effects in monkeys, which might be associated with impaired left ventricular diastolic function.
Tomomichi Ishizaka, Yu Yoshimatsu, Yu Maeda, Katsuyoshi Chiba, Kazuhiko Mori

1308 related Products with: Trastuzumab-Induced Negative Chronotropic and Lusitropic Effects in Cynomolgus Monkeys.

96T1 mg100 ul1 mg96 assays100 ul5ug 100ul50 ul100ug2ug400 ug

Related Pathways

paperclip

#34604334   2021/06/09 To Up

Hair Growth in a Patient with Alopecia Areata on Tocilizumab.

Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ.
Chloe J Walker, Kelly E Flanagan, James T Pathoulas, Isabel Pupo Wiss, Maryanne M Senna

2914 related Products with: Hair Growth in a Patient with Alopecia Areata on Tocilizumab.

2 Pieces/Box100.00 ug100 μg100.00 ug100.00 ug0.1ml (1mg/ml)100.00 ug100ug100.00 ug4 Membranes/Box100.00 ug

Related Pathways

paperclip

#34584347   2020/11/11 To Up

Grafalon® vs. Thymoglobulin® as an Induction Agent in Renal Transplantation - A Retrospective Study.

Antihuman thymocyte immunoglobulin, used as an induction agent in renal transplantation, is of two types - thymoglobulin and grafalon (formerly ATG-Fresenius). In this study, we compared outcomes with these two agents.
Pranaw Kumar Jha, Abhyudaysingh Rana, Ajay Kher, Shyam Bihari Bansal, Sidharth Sethi, Ashish Nandwani, Manish Jain, Dinesh Bansal, Dinesh Kumar Yadav, Ashwini Gadde, Amit Kumar Mahapatra, Puneet Sodhi, Vijay Kher

2304 related Products with: Grafalon® vs. Thymoglobulin® as an Induction Agent in Renal Transplantation - A Retrospective Study.

100 μg100 μg900 tests0.1ml (1mg/ml)96 tests100 μg100 μg100 μg48 samples100 μg100 μg100 μg

Related Pathways

paperclip

#34555301   // To Up

A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.

To compare the outcomes of antihuman T lymphocyte globulin (ATG-F) and porcine antihuman lymphocyte globulin (p-ALG) as part of a conditioning regimen in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA).
Yanming Zhang, Limin Liu, Yejun Si, Miao Miao, Huiying Qiu, Xiaowen Tang, Yue Han, Chengcheng Fu, Zhengming Jin, Suning Chen, Aining Sun, Depei Wu

2390 related Products with: A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.

100ug Lyophilized96 tests100 µg100ug Lyophilized2 Pieces/Box200 100ug Lyophilized100 µg100ug Lyophilized

Related Pathways

paperclip

#34522857   2021/08/21 To Up

A resource of high-quality and versatile nanobodies for drug delivery.

Therapeutic and diagnostic efficacies of small biomolecules and chemical compounds are hampered by suboptimal pharmacokinetics. Here, we developed a repertoire of robust and high-affinity antihuman serum albumin nanobodies (Nb) that can be readily fused to small biologics for half-life extension. We characterized the thermostability, binding kinetics, and cross-species reactivity of Nbs, mapped their epitopes, and structurally resolved a tetrameric HSA-Nb complex. We parallelly determined the half-lives of a cohort of selected Nbs in an HSA mouse model by quantitative proteomics. Compared to short-lived control nanobodies, the half-lives of Nbs were drastically prolonged by 771-fold. Nbs have distinct and diverse pharmacokinetics, positively correlating with their albumin binding affinities at the endosomal pH. We then generated stable and highly bioactive Nb-cytokine fusion constructs "Duraleukin" and demonstrated Duraleukin's high preclinical efficacy for cancer treatment in a melanoma model. This high-quality and versatile Nb toolkit will help tailor drug half-life to specific medical needs.
Zhuolun Shen, Yufei Xiang, Sandra Vergara, Apeng Chen, Zhengyun Xiao, Ulises Santiago, Changzhong Jin, Zhe Sang, Jiadi Luo, Kong Chen, Dina Schneidman-Duhovny, Carlos Camacho, Guillermo Calero, Baoli Hu, Yi Shi

2784 related Products with: A resource of high-quality and versatile nanobodies for drug delivery.

100 mg10ìg100ul250 mg100ug Lyophilized200ul

Related Pathways

paperclip

#34513994   2021/09/01 To Up

Antitumor Effect of Saikosaponin A on Human Neuroblastoma Cells.

Neuroblastoma (NB) is a highly metastatic tumor in children that develops in the sympathetic nervous system and has a low curative rate. Saikosaponin A (SSA), an active ingredient isolated from the root of Radix Bupleuri, is a natural compound with various pharmacological activities and shows good application prospects in antitumors. This study investigated the antihuman NB activity of SSA and underlying mechanisms associated with its actions.
Tan Cheng, Muying Ying

2089 related Products with: Antitumor Effect of Saikosaponin A on Human Neuroblastoma Cells.

50 mg200 1.00 flask1mg200 0.5 ml100.00 ug0.1ml (1mg/ml)1 mL1.00 flask25 100 ug/vial

Related Pathways